Relationship Between Prothrombin Activation Fragment F1.2 and International Normalized Ratio in Patients With Atrial Fibrillation
- 1 June 1997
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Stroke
- Vol. 28 (6) , 1101-1106
- https://doi.org/10.1161/01.str.28.6.1101
Abstract
Background and Purpose The prothrombin time (expressed as the international normalized ratio [INR]) is the standard method of monitoring warfarin therapy in patients with atrial fibrillation. Prothrombin activation fragment F1.2 provides an index of in vivo thrombin generation and might provide a better index of the effective intensity of anticoagulation. We examined the relationship between F1.2 and INR in patients with atrial fibrillation. Methods We measured INR and F1.2 levels in 846 patients with atrial fibrillation participating in the Stroke Prevention in Atrial Fibrillation III study. Two hundred nineteen (26%) were taking aspirin alone, 326 (39%) were taking adjusted-dose warfarin, and 301 (36%) were taking a low fixed dose of warfarin (1 to 3 mg) plus aspirin (combination therapy). F1.2 levels were measured with an enzyme-linked immunosorbent assay. Results Patients receiving adjusted-dose warfarin or combination therapy had significantly higher INR and significantly lower F1.2 values than those on aspirin alone ( P ≤.0001 for each of the four comparisons). F1.2 values (nanomolar) were inversely correlated with INR (F1.2=−0.1+2.3[1/INR]; R 2 =.37; P <.0001; simple linear regression). However, significant variability remained. Among patients receiving warfarin, older patients had higher F1.2 values than younger patients after adjustment for INR intensity ( P <.001) in the model. There was no difference in the relationship between F1.2 and INR between men and women. Conclusions Increasing intensity of anticoagulation, as measured by the INR, is associated with decreasing thrombin generation as measured by the F1.2 level, but significant variability exists in this relationship. Older anticoagulated patients have higher F1.2 values than younger patients at equivalent INR values. The clinical significance of these differences is not clear. F1.2 measurement might provide information regarding anticoagulation intensity in addition to that reflected by the INR.Keywords
This publication has 30 references indexed in Scilit:
- Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarctionThe American Journal of Cardiology, 1996
- An Analysis of the Lowest Effective Intensity of Prophylactic Anticoagulation for Patients with Nonrheumatic Atrial FibrillationNew England Journal of Medicine, 1996
- Management of Atrial Fibrillation in Adults: Prevention of Thromboembolism and Symptomatic TreatmentMayo Clinic Proceedings, 1996
- Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The stroke prevention in atrial fibrillation studyJournal Of Stroke & Cerebrovascular Diseases, 1995
- Optimal Oral Anticoagulant Therapy in Patients with Nonrheumatic Atrial Fibrillation and Recent Cerebral IschemiaNew England Journal of Medicine, 1995
- Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses.Journal of Clinical Investigation, 1987
- Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study.Journal of Clinical Investigation, 1987
- Association between time of increased fibrinopeptide A levels in plasma and episodes of spontaneous angina: A controlled prospective studyAmerican Heart Journal, 1987
- Markers of Fibrinogen Derivatives Used in Clinical InvestigationSeminars in Thrombosis and Hemostasis, 1985
- Rapid radioimmunoassay of human fibrinopeptide A — Removal of cross-reacting fibrinogen with bentoniteThrombosis Research, 1980